Sponsor: 
Pfizer Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Quadrivalent meningococcal conjugate vaccines

Registered for use in people aged ≥6 weeks.

MenACWY-TT — quadrivalent meningococcal (serogroups A, C, W, Y)–tetanus toxoid conjugate vaccine

Lyophilised powder in a monodose vial with separate pre-filled syringe or ampoule of solvent.

Each 0.5 mL reconstituted dose contains:

  • 5 µg meningococcal polysaccharide serogroup A
  • 5 µg meningococcal polysaccharide serogroup C
  • 5 µg meningococcal polysaccharide serogroup W
  • 5 µg meningococcal polysaccharide serogroup Y
  • 44 µg tetanus toxoid protein

May contain traces of:

  • trometamol
  • sucrose

For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Page history

Last updated: 
27 September 2021
Last reviewed: 
27 September 2021